Cargando…
A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants
BACKGROUND AND OBJECTIVE: Palovarotene is an oral, selective retinoic acid receptor gamma agonist under investigation for fibrodysplasia ossificans progressiva (FOP). Palovarotene is primarily metabolized by cytochrome P450 (CYP) 3A4. Differences in CYP-mediated metabolism of CYP substrates have bee...
Autores principales: | Dube, Louise, Haga, Nobuhiko, Grogan, Donna, Ogier, Julien, Le Quan Sang, Kim-Hanh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011291/ https://www.ncbi.nlm.nih.gov/pubmed/36802022 http://dx.doi.org/10.1007/s13318-023-00815-x |
Ejemplares similares
-
The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug–Drug Interaction in Healthy Participants
por: Marino, Rose, et al.
Publicado: (2023) -
Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants
por: Barth, Aline, et al.
Publicado: (2022) -
A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution
por: Foster, William J., et al.
Publicado: (2022) -
Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022) -
Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva
por: Pignolo, Robert J., et al.
Publicado: (2023)